Company profile
BriaCell Therapeutics Corp.
NASDAQ:BCTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SV-BR-1-GM | phase3 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06471673 | phase1_2 | unknown | 2024-05-29 | 2025-04-30 | BriaCell Therapeutics Corporation | A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer |
| NCT03328026 | phase1_2 | completed | 2018-03-16 | 2026-03-24 | BriaCell Therapeutics Corporation | Combination Study of SV-BR-1-GM With Retifanlimab |
| NCT03066947 | phase1_2 | completed | 2017-05-05 | 2018-11-22 | BriaCell Therapeutics Corporation | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer |
| NCT06072612 | phase3 | recruiting | 2023-12-05 | 2027-12-01 | BriaCell Therapeutics Corporation | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
FDA applications (0)
No records yet.